Research programme: therapeutic agents - AstraZeneca/Jubilant Biosys

Drug Profile

Research programme: therapeutic agents - AstraZeneca/Jubilant Biosys

Latest Information Update: 24 Jun 2011

Price : $50

At a glance

  • Originator Jubilant Biosys
  • Developer AstraZeneca; Jubilant Biosys
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Cardiovascular disorders; Cognition disorders; Metabolic disorders; Neurological disorders; Pain; Psychiatric disorders

Most Recent Events

  • 24 Jun 2011 Early research in Cognition disorders, Neurological disorders, Pain and Psychiatric disorders is ongoing
  • 24 Jun 2011 Early research in Metabolic disorders (unspecified route)
  • 24 Jun 2011 Early research in Cardiovascular disorders (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top